Treatment of childhood absence epilepsy-an Evidence-based answer at last!

Epilepsy Currents

Volumn 11, Issue 1, 2011, Pages 12-19

  Buchhalter, Jeffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHOSUXIMIDE; LAMOTRIGINE; VALPROIC ACID;

ATTENTION DISTURBANCE; BENIGN CHILDHOOD EPILEPSY; CHILD; CHILDHOOD ABSENCE EPILEPSY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EVIDENCE BASED PRACTICE; HUMAN; NEUROPSYCHOLOGY; NOTE; PANCREATITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84859039321     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7511-11.1.12     Document Type: Note

References (29)

1. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC, Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New Engl J Med 2010;362:790-799.
2. Loiseau P. Childhood absence epilepsy. In: Epileptic Syndromes in Childhood and Adolescence. (Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds.) CITY: John Libbey & Company Ltd, 1992:135-150.
3. Adie WJ. Pyknolepsy: A form of epilepsy in children, with a good prognosis. Proc Royal Soc Med 1924:17:19-25.
4. Gibbs FA, Davis H, Lennox WG. The EEG in epilepsy and in conditions of impaired consciousness. Arch Neurol Psychiatry MONTH 1935:1134-1148.
5. Zimmerman FT. Use of methylphenyl-succinimide in treatment of petit mal epilepsy. AMA Arch Neurol Psychiatry 1951;66:156-162.
6. Zimmerman FT, Burgemeister BB. A new drug for petit mal epilepsy. Neurology 1958;8:769-775.
7. Holmes GL, McKeever M, Adamson M. Absence seizures in children: Clinical and electroencephalographic features. Annals Neurol 1987;21:268-273.
8. Appleton RE, Beirne M. Absence epilepsy in children: The role of EEG in monitoring response to treatment. Seizure 1996;5:147-148.
9. Blomquist HK, Zetterlund B. Evaluation of treatment in typical absence seizures: The roles of long-term EEG monitoring and ethosuximide. Acta Paediatr Scand 1985;74:409-415.
10. Jeavons PM, Clark JE. Sodium valproate in treatment of epilepsy. BMJ 1974;2:584-586.
11. Callaghan N, O'Hare J, O'Driscoll D, O'Neill B, Daly M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982;24:830-836.
12. Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982;32:157-163.
13. Wallace SJ. Use of ethosuximide and valproate in the treatment of epilepsy. Neurologic Clinics 1986;4:601-616.
14. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, Womble G, Casale EJ. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-979.
15. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997;12(suppl 1):S29-S37.
16. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-367.
17. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: An open-label, randomized, parallel-group study. Epilepsia 2004;45:1049-1053.
18. Trudeau V, Myers S, LaMoreaux L, Anhut H, Garofalo E, Ebersole J. Gabapentin in naive childhood absence epilepsy: Results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996;11:470-475.
19. Verrotti A, Cerminara C, Domizio S, Mohn A, Franzoni E, Coppola G, Zamponi N, Parisi P, Iannetti P, Curatolo P. Levetiracetam in absence epilepsy. Dev Med Child Neurol 2008;50:850-853.
20. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Research 2005;64:31-34.
21. Cross JH. Topiramate monotherapy for childhood absence seizures: An open label pilot study. Seizure 2002;11:406-410.
22. Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: An open trial. Epilepsia 1993;34:305-311.
23. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-1120.
24. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: Expert opinion, 2005. J Child Neurol 2005;20(suppl 1):S1-S56; quiz S59-S60.
25. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9:353-412.
26. Posner EB, Mohamed K, Marson AG. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure 2005;14:117-122.
27. Penovich PE, Willmore LJ. Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy. Epilepsia 2009;50(suppl 8):37-41.
28. Arzimanoglou A, Ryvlin P, Perucca E. When the past challenges the present: Are older antiepileptic drugs still the best choice in childhood absence epilepsy? Lancet Neurology 2010;9:457-459.
29. Vining EP. Ethosuximide in childhood absence epilepsy: Older and better. N Eng J Med 2010;362:843-845.